Skip to main
CGON

CGON Stock Forecast & Price Target

CGON Analyst Ratings

Based on 10 analyst ratings
Buy
Strong Buy 40%
Buy 60%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

CG Oncology is a promising late-stage clinical biopharmaceutical company with a potential best-in-class asset, cretostimogene grenadenorepvec, for the treatment of bladder cancer, with potential for significant market share in multiple indications. The company's strong pipeline, progress towards a BLA filing, and potential for multiple upcoming catalysts make it an exciting investment opportunity. Despite increasing spend, the company has a strong cash position to fund its operations through 2029, and a potentially lucrative peak revenue opportunity of $3.3 billion by 2034.

Bears say

CG Oncology is currently focusing on developing its late-stage product candidate, cretostimogene grenadenorepvec, for bladder cancer patients. While the company is conducting multiple trials and has a potential $1.2 billion peak sales opportunity, there are still questions surrounding the durability of the efficacy data, interpretation of stage reclassifications in the dataset, and tolerability differences between arms. Additionally, there is a clinical risk and potential challenges in achieving regulatory and commercial success. Overall, there are uncertainties that could impact the company's financial performance and make it a risky investment at this time.

CGON has been analyzed by 10 analysts, with a consensus rating of Buy. 40% of analysts recommend a Strong Buy, 60% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of CG oncology Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About CG oncology Inc (CGON) Forecast

Analysts have given CGON a Buy based on their latest research and market trends.

According to 10 analysts, CGON has a Buy consensus rating as of Aug 13, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $81.90, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $81.90, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

CG oncology Inc (CGON)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.